AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05412160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
Study NCT05523791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortiral
Description: Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
Study NCT05523791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mg++
Description: Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
Study NCT06463002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory blood pressure monitoring and Montreal Cognitive Assessment
Description: Noninvasive tests to assess blood pressure control and cognition
Study NCT05553964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In Vitro
Description: In vitro diagnostic test for COVID-19 using anterior nasal swabs.
Study NCT05104034 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Osteoporosis screening and treatment as needed
Description: All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
Study NCT05104034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoporosis screening and treatment as needed
Description: All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
Study NCT05104034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Description: Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
Study NCT05104034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: TheraBand (resistance band) was utilized as the exercise tool within the community. T
Study NCT05104034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
Study NCT05104034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
Study NCT06397898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Viewing an educational video before Novasure treatment
Study NCT05413707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of the posterior malleolus fractures
Description: Fixation of the posterior malleolus fracture with screws and or plating.
Study NCT05413707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of lateral and/or medial malleolus fractures
Description: Fixation with screws and/or plating
Study NCT05413707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation of lateral and/or medial malleolus fractures
Description: Fixation with screws and/or plating
Study NCT05413707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syndesmotic fixation
Description: Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
Study NCT05413707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Syndesmotic fixation
Description: Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
Study NCT06196333 — intervention group
Intervention type: DEVICE
Intervention: Non-contact specular microscopy
Description: using specular microscope to do morphological examination of corneal endothelial cells
Study NCT05976503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tunodafil Hydrochloride Tablets
Description: 100mg Tunodafil Hydrochloride Tablets
Study NCT05976503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06246890 — intervention group
Intervention type: OTHER
Intervention: Autism ALERT
Description: Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
Study NCT05071677 — intervention group
Intervention type: PROCEDURE
Intervention: Discussion
Description: Participate in treatment planning meeting
Study NCT05071677 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participate in interview
Study NCT05976503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: 0.5 g/kg alcohol
Study NCT05855005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTC Hearing Aids
Description: DTC hearing aid programmed to the individual participant.
Study NCT06441175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intubation device order
Description: D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy.
Study NCT06213142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBToolkit
Description: CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
Study NCT05071677 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT05081011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Assistant Device
Description: Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
Study NCT05081011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Voice Assistant Device
Description: Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
Study NCT05361499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sp_6B
Description: Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
Study NCT05361499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg
Description: Amoxicillin, 7 days, 2x 500 mg
Study NCT04567459 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premium Amino Acids
Description: after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
Study NCT05715684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Training
Description: Virtually supervised exercise training for four weeks prior to cystectomy
Study NCT05256420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Application of a kinesiotape bandage on the knee.
Study NCT05256420 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bandage
Description: Application of a sham bandage on the knee.
Study NCT05715684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutritional Intervention
Description: Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
Study NCT06317623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prenatal and postnatal ultrasound examination
Description: Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
Study NCT06135701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: One-legged knee-extensor exercise with Doppler measurements
Description: Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
Study NCT05820308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Companion Dog Walking
Description: Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
Study NCT05820308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
Study NCT06476457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAIR Coach
Description: STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
Study NCT05867472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Inhalant Product
Description: Isoflurane will be administered using an inhalation device
Study NCT05867472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalant product
Description: Sevoflurane will be administered using an inhalation device
Study NCT05238012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule
Description: Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
Study NCT05238012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets
Description: Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
Study NCT05331287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position
Description: Influence of different head position on nasal endotracheal intubation
Study NCT06300242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders
Study NCT06300242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: $50 financial incentive for getting vaccinated within 1-week
Study NCT06300242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: No special messages or incentives
Study NCT04827329 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
Study NCT05670548 — intervention group
Intervention type: OTHER
Intervention: Questionnaire survey and specimen collection
Description: A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
Study NCT04995133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: intravenous administration
Study NCT06061653 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IPT plus HD-tDCS
Description: psychotherapy plus device
Study NCT06061653 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: IPT plus sham HD-tDCS
Description: psychotherapy plus sham device
Study NCT06543173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Catheter-based VT Ablation
Description: Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
Study NCT05037487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: Smoked placebo cannabis
Study NCT05037487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg CBD Cannabis
Description: Smoked cannabis with CBD
Study NCT05037487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg CBD + 20 mg THC Cannabis
Description: Smoked cannabis with CBD and THC
Study NCT05037487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg THC Cannabis
Description: Smoked cannabis with THC
Study NCT06434584 — intervention group
Intervention type: OTHER
Intervention: without AI assistance
Description: provide insulin dosage and confidence score without AI assistance
Study NCT05562180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized meal plan and grocery delivery
Description: Participants will use an app to customize their meal plans
Study NCT05081063 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Routine labs
Description: Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
Study NCT05081063 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Routine labs
Description: Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
Study NCT05018806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05018806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05170750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foams
Description: Every subject will perform 24 randomized trials on force platform.
Study NCT05170750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam / Orthopedic insole
Description: 3/5 of the initial population will perform static and locomotion task, with randomized conditions.
Study NCT05507632 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donafenib plus Sintilimab in combination with transarterial chemoembolisation
Description: Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
Study NCT02709031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cicletanine + magnesium
Description: Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses.
Study NCT06434584 — intervention group
Intervention type: OTHER
Intervention: with AI dosage assistance
Description: provide insulin dosage and confidence score with AI dosage assistance
Study NCT06434584 — intervention group
Intervention type: OTHER
Intervention: with explainable AI assistance
Description: provide insulin dosage and confidence score with explainable AI assistance
Study NCT02709031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cicletanine
Description: Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
Study NCT06434584 — intervention group
Intervention type: OTHER
Intervention: with faulty explainable AI assistance
Description: provide insulin dosage and confidence score with faulty explainable AI assistance
Study NCT06341946 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic third ventriculostomy
Description: role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
Study NCT06550700 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic hybrid surgery (LHS)
Description: First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
Study NCT04704570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Spinal stabilization exercise
Study NCT04704570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal stabilization exercise
Study NCT04704570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Remotely and face to face evaluation of Functional Capacity Level
Description: Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
Study NCT05896644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eat Well
Description: A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
Study NCT05662904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
Description: CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
Study NCT05662904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
Study NCT03929289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Facilitation
Description: During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
Study NCT04912323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold
Description: Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
Study NCT05970666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE with adebrelimab and bevacizumab
Description: TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
Study NCT05517538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography-Needle Intramuscular Drug guidance
Description: EMG-guided needle neurotoxin injection
Study NCT05517538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A injection into the Corrugator Supercilii muscle